Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2012

Figures & data

Figure 1. Disposition chart at 12 months. Chart showing breakdown of trials assessment at 12 months. Trials completing within the 12 months prior to 31 July 2013 were not required to have reported by 31 July 2014 (the study end date).

Table 1. Number of completed company-sponsored clinical trials relating to 23 new medicines approved in 2012 which had disclosed results, grouped by phase of study.

Phase	Total trials	Unevaluable at 12 months*	Results disclosed within 12 months#	Unevaluable at 31 July 14*		Results disclosed by 31 July 14
I/II	235	22	187/213	88%	22	191/213	90%
III	143	24	114/119	96%	24	115/119	97%
IV	9	4	4/5	80%	4	4/5	80%
other	5	2	2/3	67%	2	2/3	67%
Total	392	52	307/340	90%	52	312/340	92%

*Unevaluable if a key date was missing or unclear, or 12 months had not elapsed since trial completion.

#Twelve months measured from the later of either the date of first regulatory approval (Europe or US) or trial completion date.